

To,
BSE Limited
P.J. Towers,
Dalal Street, Mumbai — 400001

Date: 17.11.2024

Dear Sir/ Madam,

Sub: Audited Financial Results for the Quarter and year ended 31.03.2022

Unit: Sangam Health Care Products Limited (Scrip Code: 531625)

With reference to the subject cited, please find attached the audited financial results for the quarter ended 31.03.2022.

This is for the information and records of the Exchange, please.

Thanking you.

Yours truly,

For Sangam Health Care Products Limited

A. Bala Gopal



A. Bala Gopal
Chief Executive officer

SCHEDULE III OF COMPANIES ACT, 2013
PART II - AUDITED STANDALONE STATEMENT OF PROFIT AND LOSS FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2022

 Name of the Company - **SANGAM HEALTH CARE PRODUCTS LIMITED**

 Profit and Loss Statement for the Quarter and Year ended **31ST MARCH, 2022**

(Rs. In Lakhs)

Particulars	STANDALONE FINANCIALS				
	Quarter Ended			Year Ended	
	31-03-2022	31-12-2021	31-03-2021	31-03-2022	31-03-2021
	audited	Unaudited	audited	Audited	Audited
I Revenue From Operations	358.86	370.58	105.41	870.43	953.71
II Other Income	0.00	6.90	1.78	0.00	1.78
III Total Revenue (I+II)	358.86	377.48	107.19	870.43	955.48
IV Expenses					
Cost of Materials Consumed	177.15	309.04	73.47	592.86	391.19
Purchases of Stock-in-trade	0.00	-	-	-	-
Changes in inventories of finished goods Work-in-progress and Stock-in-trade	-21.19	(30.22)	18.70	(61.34)	174.05
Employee benefits expense	80.59	97.22	(145.20)	201.65	291.61
Finance Costs	0.84	10.33	6.77	11.17	7.42
Depreciation and Amortisation expense	39.04	27.56	27.56	121.72	121.72
Other Expenses	43.83	87.85	29.31	177.00	228.56
Total Expenses	320.26	501.78	10.61	1,043.06	1214.55
V Profit/ (Loss) before Exceptional Items and tax (III-IV)	38.59	(124.29)	96.58	(172.63)	-259.06
VI Exceptional Items	-	-	-	-	-
VII Profit / (Loss) from before tax (V- VI)	38.59	(124.29)	96.58	(172.63)	-259.06
VIII Tax Expense:					
Current Tax	-	-	-	-	0.00
Deferred Tax	-	-	-	(17.87)	(29.19)
IX Profit/ (Loss) for the period from continuing operations (IX-X)	38.59	(124.29)	96.58	(154.76)	-229.87
X Profit/ (Loss) from discontinuing operations	-	-	-	-	-
XI Tax Expense of discontinuing operations	-	-	-	-	-
XII Profit/ (Loss) from discontinuing operations after tax	-	-	-	-	-
XIII Profit/(loss) for the Period (IX+XII)	38.59	(124.29)	96.58	(154.76)	-229.87
XIV Other Comprehensive Income					
A). (i) Items that will not be recycled to profit or loss	-	-	-	-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
B). (i) Items that may be reclassified to profit or loss	-	-	-	-	-
(ii) Income tax on items that may be reclassified to profit or loss	-	-	-	-	-
Total Comprehensive Income	-	-	-	-	-
XV Total Comprehensive Income for the period (XIII+XIV)	38.59	(124.29)	96.58	(154.76)	(229.87)

To,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400001

Date: 07.09.2022

Dear Sir,

Sub: Declaration pursuant to regulation 33 (3) (d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 for Unmodified Opinion.

Ref: Sangam Health Care Products Ltd (BSE Scrip Code: 531625)


I, Ashok Kumar Jain, Managing Director of M/s. Sangam Health Care Products Limited hereby declare that, the Statutory Auditors of the company, M/s. M.M.Reddy & Co., Chartered Accountants have issued an Audit Report with unmodified/unqualified opinion on Standalone & Consolidated financial results of the company for year ended 31st March, 2022.

This declaration is issued in compliance of Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended vide Circular No. CIR/CFD/CMD/ 56/2016 dated 27-05-2016.

Thanking you,

Yours faithfully,

For Sangam Health Care Products Limited



D. Bhagat Reddy
Managing Director

To,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400001

Date: 07.09.2022

Dear Sir,

Sub: Declaration pursuant to regulation 33 (3) (d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 for Unmodified Opinion.

Ref: Sangam Health Care Products Ltd (BSE Scrip Code: 531625)


I, Ashok Kumar Jain, Managing Director of M/s. Sangam Health Care Products Limited hereby declare that, the Statutory Auditors of the company, M/s. M.M.Reddy & Co., Chartered Accountants have issued an Audit Report with unmodified/unqualified opinion on Standalone & Consolidated financial results of the company for year ended 31st March, 2022.

This declaration is issued in compliance of Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended vide Circular No. CIR/CFD/CMD/ 56/2016 dated 27-05-2016.

Thanking you,

Yours faithfully,


For Sangam Health Care Products Limited



D. Bhagat Reddy
Managing Director

XVI	Earnings Per Equity Share of face value of Rs.10/- each)(for Countinuing opertions):					
	1) Basic	0.26	(0.84)	0.65	(1.04)	-1.55
	2)Diluted	0.26	(0.84)	0.65	(1.04)	-1.55
XVII	Earnings Per Equity Share of face value of Rs.10/- each) (for Discountinuing opertions):					
	1) Basic	0.00	0.00	0.00	0.00	0.00
	2)Diluted	0.00	0.00	0.00	0.00	0.00
XVIII	Earnings Per Equity Share of face value of Rs.10/- each) (for Continued and Discountinuing opertions):					
	1) Basic	0.26	(0.84)	0.65	(1.04)	-1.55
	2)Diluted	0.26	(0.84)	0.65	(1.04)	-1.55
XIX	Paid-up equity share capital (Face Value of Rs. 10/- per share)	1,486.00	1,486.00	1,486.00	1,486.00	1486.00

NOTES:

1	The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 07/09/2022 in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2	The company adopted the Indian Accounting standards (Ind AS) and accordingly these results have been prepared in accordance with the recognition and measurent principles laid down in the Ind AS- 34 "Interim Financial Reporting" prescribed under Section 133 of Companies Act, 2013 read with teh relevant rules issued thereunder and other accounting propouncements generally accepted in India. The Ind-AS Compliant Standalone Financial results for the corresponding quarter and Year ended 31.03.2022 have been stated in terms of SEBI Circular dated July, 05, 2016.
3	The Company is engaged in manufaturing and selling of Medical Products. As there are no different separate reportable segments, Segment reporting as per Ind AS -108 "Operating Segments" is not applicable.
4	Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.
	<p style="text-align: right;">For SANGAM HEALTH CARE PRODUCTS LIMITED</p> <p style="text-align: center;"><i>A. Balagopal</i></p> <p style="text-align: center;">A. Balagopal Managing Director DIN: 01712903</p> <div style="text-align: right;">  </div> <p>Place: Hyderabad Date : 07/09/2022</p>

SANGAM HEALTH CARE PRODUCTS LIMITED
CIN NO- L24230TG1993PLCO16731
Statement of Financial Position as at March 31, 2022

(Amt in Rs.Lakhs)

	Particulars	Note No.	As at March 31, 2022	As at March 31, 2021
I	ASSETS			
1	Non-current assets			
	(a) Property, plant and equipment	3	380.51	502.23
	(b) Right to use assets		-	-
	(c) Capital work in progress		-	-
	(d) Investment properties		-	-
	(e) Good will		-	-
	(f) Other intangible Assets		-	-
	(g) Intangible Assets under Development		-	-
	(h) Biological Assets other than Bearer Plants		-	-
	(d) Financial assets		-	-
	(i) Investments		-	-
	(ii) Trade receivables		-	-
	(iii) Loans		-	-
	(vi) other Financial assets		-	-
	(e) Deferred Tax Asset (Net)		-	-
	(f) Other non-current asset	4	33.59	52.35
	Total non-current assets (A)		414.10	554.58
2	Current assets			
	(a) Inventories	5	194.24	105.79
	(a) Financial assets		-	-
	(i) Investments		-	-
	(ii) Trade receivables	6	61.10	68.84
	(iii) Cash and cash equivalents	7	1.21	3.44
	(iv) Bank Balances other than (iii) above		-	-
	(iv) other financial assets		-	-
	(b) Current Tax Asset (Net)	8	-	0.79
	(c) Other current assets		238.92	208.48
	Total current assets (B)		495.47	387.34
	Non Current Assets Classified as Held for Sale (C)		-	-
	Total assets (A+B+C)		909.58	941.92
II	EQUITY AND LIABILITIES			
1	Equity			
	(a) Equity share capital	9	1,486.07	1,486.07
	(b) Other equity	10	(3,462.55)	(3,374.30)
	Total equity (A)		(1,976.48)	(1,888.23)
2	Liabilities			
(i)	Non-current liabilities			
	(a) Financial Liabilities			
	(i) Borrowings	11	29.78	38.89
	(ii) Trade Payables		-	-
	(iii) Other Financial Liabilities		-	-
	(b) Long term provisions		-	-
	(c) Deferred tax Liabilities(Net)	8	22.11	106.48
	(d) Other non Current Liabilities		-	-
	Total non-current liabilities (B)		51.88	145.36
(ii)	Current liabilities			
	(a) Financial liabilities			
	(i) Borrowings	12	2,310.19	1,782.53
	(ii) Trade payables	13	279.24	441.16
	(iii) Other financial liabilities		-	-
	(b) Short term provisions		-	-
	(c) Other current liabilities	14	244.73	461.10
	(d) Current Tax Liabilities (net)		-	-
	Total current liabilities (C)		2,834.17	2,684.79
	Total liabilities (D+B+C)		2,886.05	2,830.15
	Total equity and liabilities (A+D)		909.58	941.92

The notes are an integral part of the financial statements

1-2

As per our Report of even date

For M M REDDY & CO.,
Chartered Accountants
Firm Reg No:010371/S

CA. M. Madhusudhana Reddy
Partner
Membership No: 213077

Place: Hyderabad
Date : 07.09.2022

For and on behalf of the Board of Directors
SANGAM HEALTH CARE PRODUCTS LIMITED

(Signature)
D. Bhagat Reddy
Managing Director
DIN:07087331

(Signature)
Padma Ghanakota
Director
DIN:07078176

(Signature)
V. Satish Kumar
C.F.O
PAN: ACLPV7670E



UDIN: 22213077AXHEYL7203

Generated on: 30/09/2022

SANGAM HEALTH CARE PRODUCTS LIMITED

CIN NO- L24230TG1993PLC016731

Statement of Profit and Loss and Other Comprehensive Income for the Period ended March 31, 2022.

(Amt in Rs.Lakhs)

	Note No.	For the year ended March 31, 2022	For the year ended March 31, 2021
Continuing Operations			
I Revenue from operations	15	870.43	953.71
II Other income	16	-	1.78
Net gain on de-recognition of financial assets at amortised cost		-	-
III Net gain on reclassification of financial assets		-	-
IV			
V Total income		870.43	955.48
VI Expenses			
(a) Cost of material Consumed	17	592.86	391.19
(b) Purchase of Stock in Trade			
(c) Changes in stock of finished goods, work-in progress and stock-in-trade	18	(61.34)	174.05
(d) Employee benefits	19	201.65	291.61
(e) Finance cost	20	11.17	7.42
(f) Depreciation expense	3	121.72	121.72
(g) Impairment expenses/losses		-	-
(h) Net loss on de-recognition of financial assets at amortized cost		-	-
(i) Net loss on reclassification of financial assets		-	-
(c) Other expenses	21	177.00	228.56
Total expenses (VI)		1,043.05	1,214.55
VII Profit/(loss) before Share of profit/(loss) of associates / joint ventures, exceptional items and tax (V - VI)		(172.61)	(259.06)
VIII Share of profit/(loss) of associates			
Share of profit/(loss) of joint ventures			
IX Profit/(Loss) before exceptional items and tax		(172.61)	(259.06)
X Exceptional itmes			
XI Profit before Tax		(172.61)	(259.06)
XII Tax expense :			
a. Current tax		-	-
b. Deferred tax		(17.87)	37.31
XIII Profit/(loss) for the year from continuing operations (XI-XII)		(154.74)	(296.37)
Discontinued Operations			
XIV Profit/(loss) from discontinued operations		-	-
XV Tax Expense of discontinued operations		-	-
XVI Profit/(loss) from discontinued operations (XIV +XV)		-	-
XVII XVII Profit/(loss) for the year (XIII+XVI)		(154.74)	(296.37)
XIX Other comprehensive income			
A (i) Items that will not be recycled to profit or loss			
(a) Changes in revaluation surplus		-	-
(b) Remeasurements of the defined benefit liabilities / (asset)		-	-
(c) Equity instruments through other comprehensive income		-	-
(d) Fair value changes relating to own credit risk		-	-
(e) Others (specify nature)		-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss		-	-
B (i) Items that may be reclassified to profit or loss			
		-	-

li. Padar...



SANGAM HEALTH CARE PRODUCTS LIMITED

CIN NO- L24230TG1993PLC016731

(a) Exchange differences in translating the financial statements of foreign operations	-	-
(b) Debt instruments through other comprehensive income	-	-
(c) Effective portion of gains and loss on designated portion of hedging instruments in a cash flow hedge	-	-
(d) Share of other comprehensive income of equity accounted investees	-	-
(e) Others (specify nature)	-	-
(ii) Income tax on items that may be reclassified to profit or loss	-	-
Total other comprehensive income	-	-
IX. Total comprehensive income for the year (V+ VI)	(154.74)	(296.37)
X. Earning per equity share (for Continuing Operations)		
(i) Basic	(1.04)	(1.99)
(ii) Diluted.	(1.04)	(1.99)
XI. Earnings per equity share (for discontinued operation):		
(i) Basic	(0.01)	(0.01)
(ii) Diluted.	(0.01)	(0.01)
XII. Earnings per equity share (for Continued and discontinued operation):		
(i) Basic	(1.05)	(2.01)
(ii) Diluted.	(1.05)	(2.01)

The notes are an integral part of the financial statements

1-2

As per our Report of even date

For **M M REDDY & CO.,**

Chartered Accountants

Firm Reg No:010371S

CA. M. Madhusudhana Reddy
Partner

Membership No: 213077

Place: Hyderabad

Date : 07.09.2022



For and on behalf of the Board of Directors
SANGAM HEALTH CARE PRODUCTS LIMITED

P. Padma
Padma Ghanakota
Director
DIN:07078176

D. Bhagat Reddy
D. Bhagat Reddy
Managing Director
DIN:07087331

V. Satish Kumar
V. Satish Kumar
C.F.O
PAN: ACLPV7670E



UDIN: 22213077AXHEYL7203

Generated on: 30/09/2022

SANGAM HEALTH CARE PRODUCTS LIMITED

CIN:L24230TG1993PLC016731

Cash Flow Statement for the year ended 31st March, 2022

(Amt in Rs.Lakhs)

Particulars	31.03.2022	31.03.2021
	(₹)	(₹)
A. CASH FROM OPERATING ACTIVITIES		
(Loss)/Profit before tax and extraordinary items	(172.61)	(259.06)
Adjustment for:		
Income tax expense recognised in profit or loss		-
Finance costs recognised in profit or loss	11.17	7.42
Investment income recognised in profit or loss	-	(1.78)
Gain on disposal of property, plant and equipment	-	-
Gain on disposal of a subsidiary	-	-
Gain on disposal of interest in former associate	-	-
Net (gain)/loss recorded in profit or loss on financial liabilities designated as at fair value through profit or loss	-	-
Net (gain)/loss arising on financial assets mandatorily measured at fair value through profit or loss	-	-
Net loss/(gain) arising held for trading financial liabilities	-	-
Hedge ineffectiveness on cash flow hedges	-	-
Net (gain)/loss on disposal of available-for-sale financial assets	-	-
Impairment loss recognised on trade receivables	-	-
Reversal of impairment loss on trade receivables	-	-
Depreciation and amortisation of non-current assets	121.72	121.72
Impairment of non-current assets	-	-
Net foreign exchange (gain)/loss	-	-
Expense recognised in respect of equity-settled share-based payments	-	-
Expense recognised in respect of shares issued in exchange for goods/services	-	-
Amortisation of financial guarantee contracts	-	-
Operating Profit before Working Capital Changes	(39.73)	(131.70)
Movement for Working Capital:		
(Increase)/decrease trade receivables	7.75	(18.74)
(Increase)/decrease in inventories	(88.45)	265.47
(Increase)/decrease in other assets	(11.68)	(11.19)
(Increase)/decrease in Deferred Tax	0.79	-
Increase/(decrease) in other payables	(161.92)	(150.92)
Increase/(decrease) in provisions	-	-
(Decrease)/increase in deferred revenue	-	-
(Decrease)/increase in other liabilities	(216.36)	60.88
Cash generated from operations	(509.60)	13.80
- Income taxes paid	-	-
Net Cash flow before extraordinary items	(509.60)	13.80
-Extraordinary & Prior period items	-	-
NET CASH FROM OPERATING ACTIVITIES	(509.60)	13.80

B. CASH FLOW FROM INVESTING ACTIVITIES:

Particulars	31.03.2022	31.03.2021
B. CASH FLOW FROM INVESTING ACTIVITIES:		
Payments to acquire financial assets	-	-
Proceeds on sale of financial assets	-	-
Interest received	-	1.78
Royalties and other investment income received	-	-
Dividends received from associates	-	-
Other dividends received	-	-



Amounts advanced to related parties	-	-
Repayments by related parties	-	-
Payments for property, plant and equipment	-	-
Proceeds from disposal of property, plant and equipment	-	-
Payments for investment property	-	-
Proceeds from disposal of investment property	-	-
Payments for intangible assets	-	-
Net cash outflow on acquisition of subsidiaries	-	-
Net cash inflow on disposal of subsidiary	-	-
Net cash inflow on disposal of associate	-	-
NET CASH FROM INVESTING ACTIVITIES	-	1.78
C. CASH FLOW FROM FINANCING ACTIVITIES		
Particulars	31.03.2022	31.03.2021
CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from issue of equity instruments of the Company	-	-
Proceeds from issue of convertible notes	-	-
Payment for share issue costs	-	-
Payment for buy-back of shares	-	-
Payment for share buy-back costs	-	-
Proceeds from issue of redeemable preference shares	-	-
Proceeds from issue of perpetual notes	-	-
Payment for debt issue costs Proceeds from borrowings	-	-
Repayment of borrowings	518.55	62.52
Proceeds from government loans	-	-
Proceeds on disposal of partial interest in a subsidiary that does not involve loss of control	-	-
Dividends paid on redeemable cumulative preference shares	-	-
Dividends paid to owners of the Company	-	-
Interest paid	(11.17)	(7.42)
Long Term Provisions	-	(67.98)
NET CASH FROM FINANCING ACTIVITIES	507.38	(12.89)
NET INCREASE IN CASH & CASH EQUIVALENTS	(2.22)	1.68
Cash and cash equivalents at the beginning of the year	3.44	0.75
Effects of exchange rate changes on the balance of cash held in foreign currencies	-	-
Cash and cash equivalents at the end of the year	1.21	2.44
Reconciliation of cash and cash equivalents as per the cash flow Statement		
Cash and cash equivalents (Note no.7.3)	1.21	3.44
Balance as per statement of cash flows	1.21	3.44

As per our Report of even date

For M M REDDY & CO.,
Chartered Accountants
Firm Reg No:010371S

CA. M. Madhusudhana Reddy
Partner
Membership No: 213077

Place: Hyderabad
Date : 07.09.2022



For and on behalf of the Board of Directors
SANGAM HEALTH CARE PRODUCTS LIMITED

D. Bhagat Reddy
Managing Director
DIN:07087331

Padma Ghanakota
Director
DIN:07078176

V. Satish Kumar
C.F.O
PAN: ACLPV7670E



UDIN: 22213077AX HEYL7203

Generated on: 30/09/2022

SANGAM HEALTH CARE PRODUCTS LIMITED

Depreciation schedule as per companies Act,2013 for the year 2021-22

(Amt in Rs.Lakhs)

Particular	Plant & Machinery	Lab Equipments	Computers	Office Equipment	Furniture & Fixtures	Vehicles	Total
Cost/Deemed Cost:							
at 1st April 2020	2,723.63	80.86	18.95	14.41	25.86	87.39	2,951.11
Additions	-	-	-	-	-	-	-
Deletions							
As at March 2021	2,723.63	80.86	18.95	14.41	25.86	87.39	2,951.11
Additions	-	-	-	-	-	-	-
Deletions	-	-	-	-	-	-	-
As at March 2022	2,723.63	80.86	18.95	14.41	25.86	87.39	2,951.11
Depreciation/Impairment							
at 1st April 2020	2,155.29	77.23	18.69	14.34	25.68	35.93	2,327.17
Depreciation for the year	116.82	0.24	0.04	-	-	4.61	121.72
Disposals	-	-	-	-	-	-	-
Impairment	-	-	-	-	-	-	-
As at March 2021	2,272.12	77.48	18.73	14.34	25.68	40.54	2,448.88
Depreciation for the year	116.82	0.24	0.04	-	-	4.61	121.72
Disposals	-	-	-	-	-	-	-
Impairment	-	-	-	-	-	-	-
As at March 2022	2,388.94	77.72	18.77	14.34	25.68	45.15	121.72
Net Book Value							
As at March 2022	334.68	3.14	0.18	0.07	0.18	42.25	380.51
As at March 2021	451.51	3.39	0.22	0.07	0.18	46.86	502.23

SANGAM HEALTH CARE PRODUCTS LIMITED

Notes annexed to and forming part of the Financial Statements

Note.4 Other Assets Non Current Assets (Amt in Rs.Lakhs)

Particulars	As at 31st March, 2022	As at 31st March, 2021
(A) Other Non-Current Assets		
Capital Advances :		
Advances other than capital advances	-	18.76
Security Deposits:		
Government Authorities - Electricity Dept	33.59	33.59
Total of Other Non-current Assets	33.59	52.35
(B) Other Current Assets		
Capital Advances:		
Advances to Plant and Machinery	143.49	143.49
Advances other than capital advances:		
MAT Credit Entitlement	63.39	63.39
Other Advances	27.92	-
Other Advances:		
GST Input	1.76	-
TDS receivable	0.58	-
Interest Receivable	1.78	1.60
Total of Other current Assets	238.92	208.48

Note 5 Inventories

Particulars	As at 31st March, 2022	As at 31st March, 2021
Raw Material	44.22	18.53
Packing Material	31.32	29.90
Work In Process	43.95	42.03
Finished Goods	66.05	13.72
Consumables & Stores and Spares	8.71	1.61
Property under Development	-	-
Total Inventories	194.24	105.79

Note 6 Trade Receivables

Particulars	As at 31st March, 2022	As at 31st March, 2021
Unsecured considered good		
- From Others	61.10	68.84
Total Trade Receivables	61.10	68.84

Note 7 Cash and Cash Equivalents

Particulars	As at 31st March, 2022	As at 31st March, 2021
Cash and Cash Equivalents	1.21	3.44
Bank Balances other than Cash and Cash	-	-
Total Cash and Cash Equivalents	1.21	3.44

Cash and Cash Equivalents

Particulars	As at 31st March, 2022	As at 31st March, 2021
Bank and Cash Balances		
On Current Accounts:		
Kotak Bank-KNR-6912456133	0.01	0.01
Karur Vysya Bank Ltd A/C.No.140413500006078	0.11	-
Kotak Bank-356	-	0.08
Kotak Bank-295	0.34	(0.00)
SBI-CURRENT A/C.62263238738(Commerical Branch)	-	-
HDFC BANK	0.61	-
Andhra Bank	-	-
Syndicate Bank	0.15	0.03
Fixed Deposits with maturity less than 3 months	-	-
Cheques/dafts on hand	-	-
Cash on hand	0.00	3.32
Total Cash and Cash Equivalents	1.21	3.44

Note 8 Income Taxes

Particulars	As at 31st March, 2022	As at 31st March, 2021
a) Current Tax Asset		
Opening Balance	-	0.58
Add: Taxes paid/TDS Receivable	-	0.20



SANGAM HEALTH CARE PRODUCTS LIMITED

Less: Current tax payable for the year	-	-
	-	0.79
b) Differed tax Liability	-	-
on Written down value of fixed assets	(106.48)	69.17
Add/Less : Provided for the Current Year	-	37.31
Total	(106.48)	(106.48)

Note 11 Borrowings

	As at 31st March, 2022		As at 31st March, 2021	
	Non Current	Current	Non Current	Current
From banks	29.78	-	38.89	-
Interest-free sales Tax deferral loan from state Govt.	-	74.53	-	139.53
Unsecured Loans				
From Individuals other than banks	-	2,235.66	-	1,643.00
Total Borrowings	29.78	2,310.19	38.89	1,782.53

Particulars	As at 31st March, 2022	Terms of Repayment	Security
Long Term			
Bonds	-	-	-
Debentures	-	-	-
Rupee term loans from Banks:	29.78	-	-
Interest-free sales Tax deferral loan from state Govt.	-	-	-
Short Term			
Interest-free sales Tax deferral loan from state Govt.	-	-	-

Notes 12 Note Short Term Borrowings	As at 31st March, 2022	As at 31st March, 2021
Term loans		
Interest-free sales Tax deferral loan from state government	74.53	139.53
Unsecured Loans	2,235.66	1,643.00
Total	2,310.19	1,782.53

Note : Based on the nature of liability the outstanding liabilities are re-classified as current liabilities because they are payable on demand. Term loans from 18.28 lakhs from HDFC Bank Car Loan & Rs.11.50 Lakhs from Kotak Mahindra bank Car Loan Bank secured by Vehicles

Note 13 Trade payables

	As at 31st March, 2022		As at 31st March, 2021	
	Non Current	Current	Non Current	Current
Trade payables				
Dues to other than Micro, Small and Medium Enterprises	-	279.24	-	441.16
Sub total	-	279.24	-	441.16

Note: Dues to micro and small enterprises - As per Micro, Small and Medium Enterprises Development Act, 2006 ('MSMED' Act) This information has been determined to the extent such parties have been identified on the basis of information available with the Company

Note 14 Other Current Liabilities

	As at 31st March, 2022	As at 31st March, 2021
a).Revenue Received in Advance		
Advances From customers	121.94	208.14
b).Other Payables		
Statutory Dues Payable		
Provident fund payable	3.15	29.70
ESI contribution payable	0.46	0.26
Interest Payable on statutory dues	42.69	42.69
TDS payable	23.47	17.42
Salaries and Wages & settlements payable	16.89	131.00
Directors Remuneration Payable	8.40	8.40
Bonus payable	3.31	3.31
Electricity Charges Payable	7.81	2.67
Other Expenses Payable	6.43	6.68
Deposits	1.30	1.30
Other Advance payable	6.89	5.70
Audit fee payable	2.00	2.95
GST payable	-	0.88
Total	244.73	461.10



SANGAM HEALTH CARE PRODUCTS LIMITED

Notes annexed to and forming part of the Financial Statements

Note 9: Equity share capital

a. Equity share capital

(Amt in Rs.Lakhs)

	As at March 31, 2022		As at March 31, 2021	
	No. of Shares	Amount in Rs.	No. of Shares	Amount in Rs.
Authorised				
Equity shares of Rs. 10 each	1,500.00	15,000.00	1,500.00	15,000.00
Issued				
Equity shares of Rs. 10 each	148.61	1,486.07	148.61	1,486.07
Subscribed and Paid-up				
Equity shares of Rs. 10 each fully paid-up	148.61	1,486.07	148.61	1,486.07
Total	148.61	1,486.07	148.61	1,486.07

b. Reconciliation of the number of equity shares outstanding and the amount of share capital

	As at March 31, 2022		As at March 31, 2021	
	No. of Shares	Amount	No. of Shares	Amount
Equity Shares				
Issued and Subscribed:				
Shares outstanding at the beginning of the year	148.61	1,486.07	148.61	1,486.07
Add: Issued During the year for cash	-	-	-	-
Add: Shares issued at ESOP trust	-	-	-	-
Shares outstanding at the end of the year	148.61	1,486.07	148.61	1,486.07

c. Terms / rights attached to equity Shares

The company has one class of equity shares having a par value of Rs.10 per share. Each shareholder is eligible for one vote per share held. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the company after distribution of all preferential amounts, in proportion to their shareholdings.

d. Shares reserved for issue underwriter options

Nil

e. Detail of Rights Issues

Nil

f. details of shares held by Holding/Ultimatley Holding Company

Nil

g. Details of shares issued for consideration other than cash

Nil

h. Shares in the company held by each shareholder holding more than 5 percent

Name of the Shareholder	As at March 31, 2022		As at March 31, 2021	
	No. of Shares held	% of Holding	No. of Shares held	% of Holding
M/s. Boin Medica Co Ltd	1,240,260	8.35%	1,240,260	8.35%
Addepalli Balagopal	3,001,000	20.19%	3,001,000	20.19%
D.V.S.Sharma	2,500,000	16.82%	2,500,000	16.82%
G.Ramana	2,255,140	15.18%	2,255,140	15.18%
G.Padma	2,000,000	13.46%	2,000,000	13.46%

*Includes 10 Equity shares of Rs. 10 each fully paid up held by nominee.

i. Dividend Declaration Details

Amount in Rs.

Particulars	As at March 31, 2022	As at Mar 31, 2021
	Cash Dividend Declared for the Year 31st March 2022	-
Interim Dividend for the year ended on 31st March 2022		
Total	-	-
Proposed Dividend on Equity Shares	-	-
Final Dividend for the year ended 31st March 2022		
Total	-	-

Note 10.1 Other equity

	As at March 31, 2021	As at March 31, 2021
Capital Reserve:		
Balance at the beginning of the year	770.01	770.01
Add: Addition During the Year	-	-
Balance at the end of the year	770.01	770.01



Securities Premium:		
Balance at the beginning of the year	-	-
Add: Securities Premium on shares issued during the year	-	-
Balance at the end of the year	-	-
Retained earnings		
Balance at the beginning of the year	(4,077.81)	(3,847.94)
Add: Addition During the Year	(154.74)	(229.87)
Balance at the end of the year	(4,232.56)	(4,077.81)
Total other Equity	(3,462.55)	(3,307.80)

Note 10.2 Other Reserves

	As at March 31, 2021	As at March 31, 2021
Debentures Redemption Reserves:		
Balance at the beginng of the year	-	-
Add: Addition during the Year	-	-
Balance at the end of the year	-	-
Capital Redemption Reserves:		
Balance at the beginning of the year	-	-
Add: Addition during the Year	-	-
Balance at the end of the year	-	-
Investment Fluctuation Reserves:		
Balance at the beginning of the year	-	-
Add: Addition during the Year	-	-
Balance at the end of the year	-	-
Total Other Reserves	-	-



SANGAM HEALTH CARE PRODUCTS LIMITED
Notes annexed to and forming part of the Financial Statements

Note 15: Revenue from operations

(Amt in Rs.Lakhs)

Particulars	For the Year ended Mar 2022	For the year ended March 2021
A.Revenue from contracts with customers disaggregated based on nature of product or services		
Revenue from Sale of Products		
a). Sale of Manufactured Goods	870.43	953.71
b).Stock in Trade	-	-
Net Revenue	870.43	953.71
Revenue from Sale Service		
a). Software services	-	-
b). Other Services	-	-
Sub total	-	-
Other Operating Revenues		
a). Export Incentives	-	-
b).Royalty Received	-	-
From subsidiaries and associates	-	-
From others	-	-
c). Scrap Sale	-	-
d). Others	-	-
Sub total	-	-
Total Revenue from Operations	870.43	953.71

Particulars	For the Year ended Mar 2022	For the year ended March 2021
B Disaggregated revenue information		
Revenue from contracts with customers disaggregated based on geography		
a). Domestic	870.43	1,064.45
b).Export	-	-
	870.43	1,064.45
C)Reconciliation of Gross Revenue from Contracts With Customers		
Gross Revenue	870.43	1,064.45
Less: Discount	-	-
Less: Returns	-	-
Less: Price Concession	-	-
Less: Incentives and performance bonus	-	-
Less: Goods and Service Tax	-	110.74
Net Revenue recognised from Contracts with Customers	870.43	953.71

Note 16: Other Income

Particulars	For the Year ended Mar 2022	For the year ended March 2021
Interest income		
a).Financial assets mandatorily measured at fair value through profit or loss	-	-
b). Interest income on financial assets fair valued through other comprehensive income	-	-
-Non Convertible debentures	-	-
c). Financial assets carried at amortised cost	-	-
Tax free bonds and government bonds	-	-
Deposits with banks and others	-	1.78
Sub total (i)	-	1.78
Dividend Income		
a).Investments mandatorily measured at fair value through profit or loss	-	-
b).Equity investment designated at fair value through other comprehensive income	-	-
Sub total (ii)	-	-
Unwinding of discount on security deposits(iii)	-	-



Government grants (iv)	-	-
Rental income on Investment Properties (v)	-	-
Total(i+ii+iii+iv+v)	-	1.78

Note 17 Cost of Material Consumed

Particulars	For the Year ended Mar 2022	For the year ended March 2021
A. Raw Material Consumed		
Raw materials at the beginning of the year	48.43	139.76
Add: Purchases During the year	619.97	299.86
Less: Raw materials at the end of the year	75.54	48.43
Total cost of raw material consumed	592.86	391.19
B). Packing Material		
Packing materials at the beginning of the year	-	-
Add : Purchases During the year	-	-
Less: Packing materials at the end of the year	-	-
Total cost of packing materials consumed (B)	-	-
Total cost of Materials consumed (B)	592.86	391.19

Note 18 Changes in inventories of finished goods, work-in-progress and stock-in-trade

Particulars	For the Year ended Mar 2022	For the year ended March 2021
Opening Balnce		
Finished Goods	13.72	136.66
Work in Progress	42.03	92.04
Stock in Trade (Including Goods in Transit)	-	(0.09)
Spares and Consumables	1.61	2.80
Total Opening Balnces	57.36	231.41
Closing Balance		
Finished Goods	66.05	13.72
Work in Progress	43.95	42.03
Stock in Trade (Including Goods in Transit)	-	-
Spares and Consumables	8.71	1.61
Total Closing Balance	118.71	57.36
Total Changes in inventories of finished goods, work-inprogress and stock-in-trade	(61.34)	174.05

Note 19 Employee Befefits

Particulars	For the Year ended Mar 2022	For the year ended March 2021
Salaries, Wages, Bonus etc.	200.49	286.71
Contribution to P.F, E.S.I and Other Statutory Funds	-	3.87
Employee share based payment expenses	-	-
Gratuity	-	-
Leave compensation	-	-
Post-employment pension benefits	-	-
Post-employment medical benefits	-	-
Staff welfare expenses	1.16	1.02
Total Employee benefits	201.65	291.61

Note 20 Finance Cost

Particulars	For the Year ended Mar 2022	For the year ended March 2021
Interest and finance charges on financial liabilities carried at amortised cost		
a). Interest on Bank Borrowings	10.83	6.42
b). Interest on Bill Discounting	-	-
c). Other Interest Expenses (Bank Charges)	0.34	1.00
Less: Amount Capitalised	-	-
Total Interest on financial liabilities carried at amortised cost	11.17	7.42
Intest on Trade payables (as per MSME Act)	-	-
Interest on delayed payment of statutory dues	-	-



Unwinding of discount on provision	-	-
Exchange difference regarded as adjustment to borrowing costs	-	-
Dividend on redeemable preference shares (including dividend distribution tax)	-	-
Total Finance Cost	11.17	7.42

Note 21 : Other expenses

Particulars	For the Year ended Mar 2022	For the year ended March 2021
Audit Fees	2.00	2.00
Consumptions of Store and Spares	-	0.97
Power and Fuel	63.07	56.81
Factory Maintenance	7.56	6.95
Insurance	-	-
Rates and Taxes	4.59	0.19
Security Charges	4.76	3.90
Travelling & Conveyance Expenses	3.63	4.22
Printing & Stationery	0.73	0.23
Factory rent	54.66	72.20
Telephone Expense	1.37	1.02
Vehicle Maintenance	0.46	0.70
Other General Expenses	1.96	1.97
Marketing Expenses	(0.48)	27.85
Carriage Outwards	27.68	46.34
Consultancy and Legal Charges	1.90	2.16
Office Maintenance	3.11	0.98
Stock Written off	-	0.09
Total	177.00	228.56

18.6.1 Payment to Auditors

Particulars	For the Year ended Mar 2022	For the year ended March 2021
As An Auditor		
- Audit Fees	2.00	2.00
- Tax Audit	-	-
- Limited Review	-	-
In Other Capacity		
- Taxation Matters	-	-
- Company Law matters	-	-
- Certification matters	-	-
- Reimbursement of Expenses	-	-
Total Payment to Auditor	2.00	2.00

18.6.2 Corporate Social Responsibility(CSR) Not Applicable to this period

Particulars	For the Year ended Mar 2022	For the year ended March 2021
Amount required to be spent as per Section 135 of the Companies Act, 2013	-	-
Amount spent during the year on	-	-

As per our Report of even date

For M M REDDY & CO.,
Chartered Accountants
Firm Reg No:010371S

CA. M. Madhusudhana Reddy
Partner
Membership No: 213077

Place: Hyderabad
Date : 07.09.2022



SANGAM HEALTH CARE PRODUCTS LIMITED

[Signature]
Padma Ghanakota
Director
DIN:07078176

[Signature]
D. Bhagat Reddy
Managing Director
DIN:07087331
[Signature]
V. Satish Kumar
C.F.O
PAN: ACLPV7670E



UDIN: 22213077AXHEYL7203

Generated on: 30/09/2022

SANGAM HEALTH CARE PRODUCTS LIMITED

Analytical Ratios for the year ended 31st March,2022.

(Amt in Rs.Lakhs)

Ratios	Formula	2021-22	2020-21	
Operating profit margin r	EBIT/Sales*100	PBT	(172.61)	(259.06)
		ADD: interest	11.17	7.42
		SUB: other Income	-	1.78
		EBIT	(161.45)	(249.86)
		Sales	870.43	953.71
		Ratio	(18.55)	(26.20)
Net profit margin	PAT/Sales	PAT	(154.74)	(296.37)
		Sales	870.43	953.71
		Ratio	(17.78)	(31.08)
Return on equity	PAT/Networth	PAT	(154.74)	(296.37)
		networth	(1,976.48)	(1,888.23)
		Ratio	7.83	15.70
current Ratio	current assests/current Liabilities	Current assests	495.47	387.34
		current Liabilites	2,834.17	2,684.79
		Ratio	0.17	0.14
Interest Coverage ratio	EBIT/Interest	EBIT	(172.61)	(259.06)
		Interest	11.17	7.42
		Ratio	(6.47)	(2.87)
Debtor Turnover Ratio	Sales/Average Debtors	Sales	870.43	953.71
		Opening Debtors	68.84	5,010,222.00
		Closing debtors	61.10	68.84
		Average debtors	64.97	2,505,145.42
		Ratio	13.40	0.00
Stock Turnover Ratio	Sal/Average Stock	COGS	733.16	856.85
		Opening Stock	105.79	37,126,470.00
		Closing Stock	194.24	105.79
		Average Stock	150.02	18,563,287.90
		Ratio	4.89	0.00
Debt Equity Ratio	Total Liabilities/Shareholders funds	Non current Liabilities		51.88495424
		Current Liabilities		2834.166317
		Shareholders ratio		(1976.48)
		Ratio		(1.43)





INDEPENDENT AUDITORS' REPORT

TO THE BOARD OF DIRECTORS OF Sangam Health Care Products Limited

Report on the audit of the Standalone Annual Financial Results

Opinion

We have audited the accompanying standalone annual financial results of **Sangam Health Care Products Limited** (hereinafter referred to as the "Company") for the year ended 31 March 2022 ('standalone annual financial results'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financial results:

- are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net loss and other comprehensive income and other financial information for the year ended 31st March 2022.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results* section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our opinion on the Standalone annual financial results.

Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results

These standalone annual financial results have been prepared on the basis of the standalone annual financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net profit/ loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed



under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of standalone financial statements on whether the company has adequate internal financial controls with reference to standalone financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the



reasonableness of accounting estimates and related disclosures in the standalone annual financial results made by the Management and Board of Directors.

- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the standalone annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The standalone annual financial results include the results for the quarter ended 31st March 2022 being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

Our opinion on the standalone annual financial results is not modified in respect of this matter.

For **M M REDDY & CO.,**
Chartered Accountants
Firm Reg No.010371S



Date: 07-09-2022
Place: Hyderabad

M. Madhusudhana Reddy
Partner
Membership No.213077
UDIN: 22213077AXHEYL7203